Research Summary

Dr. Aaron Logan is an Associate Professor of Clinical Medicine at the University of California, San Francisco (UCSF). His clinical practice focuses on the management of patients with acute leukemias, myelodysplastic syndrome, aplastic anemia and hemophagocytic lymphohistiocytosis. Dr. Logan also runs a research laboratory and is director of the Hematologic Malignancies Tissue Bank at UCSF. Dr. Logan and his laboratory are interested in methods for evaluating clonotypic diversity in the B and T lymphocyte repertoires in patients, particularly following hematopoietic cell transplantation when used to treat blood cancers, bone marrow failure disorders, and congenital immune deficiencies. Methods used in the laboratory currently include T cell receptor excision circle and kappa-deleting recombination circle (TREC/KREC) quantification, high-throughput sequencing of immunoglobulin and T cell receptor genes, and in vitro mixed lymphocyte reactions to identify T cells with specific reactivities. Efforts in the lab are focused on the application of immune repertoire profiling to quantify and track malignancy-, pathogen-, and autoantigen-targeted immune responses following allogeneic transplantation, as well as use of this platform to quantify measurable residual disease in lymphoid malignancies. In Dr. Logan’s lab, the Hematologic Malignancies Tissue Bank at UCSF has been built into a robust resource for samples isolated from patients with a wide diversity of blood cancers and following transplantation. These samples are made available in a deidentified manner to the UCSF and larger research community for cooperative discovery.

Education

Hematology and Blood and Marrow Transplant Fellowships, Stanford University, 2013
Internal Medicine Residency (Clinical Investigator Pathway), Stanford University, 2008
MD, Keck School of Medicine of the University of Southern California, 2006
PhD, Molecular Microbiology and Immunology, Keck School of Medicine of the University of Southern California, 2006
MPhil, History of Medicine, University of Cambridge, England

Honors & Awards

  • 2020
    UCSF Hematology-Oncology Fellowship Teaching Award
  • 2012
    Abstract Award, American Society of Hematology
  • 2011
    Abstract Award, American Society of Hematology
  • 2011
    Research Training Award for Fellows, American Society of Hematology
  • 2011
    Clinical Research Training Fellow, American Society of Blood and Marrow Transplantation
  • 2006
    Highest Distinction, Keck School of Medicine of the University of Southern California
  • 2005
    Alpha Omega Alpha
  • 2005
    Dean's Recognition, Keck School of Medicine of the University of Southern California
  • 2004
    Travel Award, American Society of Gene Therapy
  • 2003
    Outstanding Teaching Award, Keck School of Medicine of the University of Southern California
  • 2003
    Excellence in Teaching in Cell and Neurobiology, Keck School of Medicine of the University of Southern California

Selected Publications

  1. Hall K, Lazaryan A, Der Laan MV, Lee CJ, Logan AC, Gruber S, Kabadi S, Khan I, Nicholls C, Rota LM, Nikai E, Ponomareva E, Koumas A, Waller EK Efficacy and Safety of Belumosudil as Compared with Best Available Therapy for the Treatment of cGVHD in the US.  View on PubMed
  2. O'Connor TE, Lin C, Roloff GW, Zhang A, Miller K, Aldoss I, Kopmar NE, Dekker SE, Gupta VK, Jeyakumar N, Muhsen IN, Valtis Y, Ahmed N, Sutherland K, Dykes KC, Ahmed M, Chen E, Zambrano H, Bradshaw D, Mercadal S, Schwartz M, Tracy S, Connor MP, Kubiak M, Mukherjee A, Majhail N, Battiwalla M, Mountjoy L, Malik SA, Mathews J, Shaughnessy P, Blunk B, Logan AC, Ladha A, Advani AS, Stefan M, Guzowski C, Hoeg RT, Hilal T, Moore J, O'Dwyer KM, Hill LC, Sasine J, Oliai C, Solh MM, Lee CJ, Kota VK, Koura D, Kumaran MV, Leonard JT, Frey NV, Park JH, Luskin MR, Bachanova V, Galal A, Pullarkat V, Bishop MR, Stock W, Cassaday RD, Shah BD, Faramand R, Muffly LS, Tsai SB, Dholaria B The impact of social determinants of health on outcomes of brexucabtagene autoleucel in adults with relapsed/refractory B-cell acute lymphoblastic leukemia.  View on PubMed
  3. Jonas BA, Fisch SC, Curtin PT, Schiller GJ, Jeyakumar D, Tzachanis D, Bejar R, Qi L, Wieduwilt MJ, Tuscano JM, Damon L, Logan AC, University of California Hematologic Malignancies Consortium A phase 1 trial of ibrutinib and azacitidine for higher risk myelodysplastic syndromes (University of California Hematologic Malignancies Consortium Study 1503).  View on PubMed
  4. Muhsen IN, Roloff GW, Faramand RG, Othman T, Valtis YK, Kopmar NE, Dekker SE, Connor M, Mercadal S, O'Connor TE, Dykes KC, Ahmed M, Jeyakumar N, Zhang A, Miller K, Sutherland KC, Guzowski C, Gupta VK, Majhail NS, Battiwalla M, Solh MM, Malik SA, Mathews J, Oliai C, Shaughnessy PJ, Mountjoy L, Lee CJ, Logan AC, Tsai SB, Leonard JT, Schwartz MS, Sasine JP, Kumaran M, Frey NV, Park JH, Koura D, Cassaday RD, Shah BD, Aldoss I, Muffly LS, Hill LC Outcomes of Brexucabtagene Autoleucel in Relapsed/Refractory Acute Lymphoblastic Leukemia Patients with CNS Involvement.  View on PubMed
  5. Othman T, Lo MM, Andreadis CB, Damon LE, Ferng TT, Gaensler KML, Lee JC, Martin TG, Olin RL, Sayre PH, Smith CC, Logan AC. Single-center experience with nelarabine, etoposide, and cyclophosphamide in adults with relapsed/refractory T-acute lymphoblastic leukemia/lymphoma. Leuk Lymphoma. 2025 May 07; 1-4.  View on PubMed
  6. Short NJ, Aldoss I, DeAngelo DJ, Konopleva M, Leonard J, Logan AC, Park J, Shah B, Stock W, Jabbour E. Clinical use of measurable residual disease in adult ALL: recommendations from a panel of US experts. Blood Adv. 2025 Mar 25; 9(6):1442-1451.  View on PubMed
  7. Shah BD, Cassaday RD, Park JH, Houot R, Logan AC, Boissel N, Leguay T, Bishop MR, Topp MS, O'Dwyer KM, Tzachanis D, Arellano ML, Lin Y, Baer MR, Schiller GJ, Subklewe M, Abedi M, Minnema MC, Wierda WG, DeAngelo DJ, Stiff P, Jeyakumar D, Mao D, Adhikary S, Zhou L, Hadjivassileva T, Damico Khalid R, Ghobadi A, Oluwole OO. Three-year analysis of adult patients with relapsed or refractory B-cell acute lymphoblastic leukemia treated with brexucabtagene autoleucel in ZUMA-3. Leukemia. 2025 Mar 19.  View on PubMed
  8. Oliai C, Park S, Damon LE, Jonas BA, Jeyakumar D, Wieduwilt MJ, Logan AC, Callas B, Hannigan CA, Gaut DL, Schiller GJ. CPX-351 plus gemtuzumab ozogamicin for relapsed/refractory acute myelogenous leukemia: a University of California Hematologic Malignancies Consortium trial. Leuk Lymphoma. 2025 Apr; 66(4):773-779.  View on PubMed
  9. Aldoss I, Roloff GW, Faramand R, Kopmar NE, Lin C, Advani AS, Dekker SE, Gupta VK, O'Connor TE, Jeyakumar N, Muhsen IN, Valtis Y, Zhang A, Miller K, Sutherland K, Dykes KC, Ahmed M, Chen E, Zambrano H, Bradshaw D, Mercadal S, Schwartz M, Tracy S, Dholaria B, Kubiak M, Mukherjee A, Majhail N, Battiwalla M, Mountjoy L, Malik SA, Mathews J, Shaughnessy P, Logan AC, Ladha A, Stefan M, Guzowski C, Hoeg RT, Hilal T, Moore J, Connor M, O'Dwyer KM, Hill LC, Tsai SB, Sasine J, Solh MM, Lee CJ, Kota VK, Koura D, Veeraputhiran M, Blunk B, Oliai C, Leonard JT, Frey NV, Park JH, Luskin MR, Bachanova V, Galal A, Bishop MR, Stock W, Cassaday RD, Pullarkat V, Shah BD, Muffly LS. Impact of prior inotuzumab ozogamicin treatment on brexucabtagene autoleucel outcomes in adults with B-cell ALL. Blood Adv. 2024 Dec 10; 8(23):6139-6147.  View on PubMed
  10. Roddie C, Sandhu KS, Tholouli E, Logan AC, Shaughnessy P, Barba P, Ghobadi A, Guerreiro M, Yallop D, Abedi M, Pantin JM, Yared JA, Beitinjaneh AM, Chaganti S, Hodby K, Menne T, Arellano ML, Malladi R, Shah BD, Mountjoy L, O'Dwyer KM, Peggs KS, Lao-Sirieix P, Zhang Y, Brugger W, Braendle E, Pule M, Bishop MR, DeAngelo DJ, Park JH, Jabbour E. Obecabtagene Autoleucel in Adults with B-Cell Acute Lymphoblastic Leukemia. N Engl J Med. 2024 Dec 12; 391(23):2219-2230.  View on PubMed
  11. Jabbour EJ, Kantarjian HM, Goekbuget N, Shah BD, Chiaretti S, Park JH, Rijneveld AW, Gore L, Fleming S, Logan AC, Ribera JM, Menne TF, Mezzi K, Zaman F, Velasco K, Boissel N. Frontline Ph-negative B-cell precursor acute lymphoblastic leukemia treatment and the emerging role of blinatumomab. Blood Cancer J. 2024 Nov 19; 14(1):203.  View on PubMed
  12. Roloff GW, Aldoss I, Kopmar NE, Lin C, Dekker SE, Gupta VK, O'Connor TE, Jeyakumar N, Muhsen IN, Valtis Y, Ahmed N, Zhang A, Miller K, Dykes KC, Ahmed M, Chen EC, Mercadal S, Schwartz M, Tracy SI, Dholaria B, Mukherjee A, Battiwalla M, Logan AC, Ladha A, Guzowski C, Hoeg RT, Hilal T, Moore J, Connor MP, Hill LC, Tsai SB, Sasine JP, Solh MM, Kota VK, Koura D, Veeraputhiran M, Leonard JT, Frey NV, Park JH, Luskin MR, Bachanova V, Galal A, Pullarkat V, Stock W, Cassaday RD, Shah BD, Faramand R, Muffly L, ROCCA Consortium. Outcomes After Brexucabtagene Autoleucel Administered as a Standard Therapy for Adults With Relapsed/Refractory B-Cell ALL. J Clin Oncol. 2025 Feb 10; 43(5):558-566.  View on PubMed
  13. Shah B, Mattison RJ, Abboud R, Abdelmessieh P, Aldoss I, Burke PW, DeAngelo DJ, Dinner S, Fathi AT, Gauthier J, Haddadin M, Jain N, Jonas B, Kirby S, Liedtke M, Litzow M, Logan A, Long M, Luger S, Mangan JK, Massaro S, May W, Oluwole O, Park J, Przespolewski A, Rangaraju S, Saygin C, Schwartz M, Shami P, Tomlinson B, Webster J, Awotiwon A, Stehman K. Acute Lymphoblastic Leukemia, Version 2.2024, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2024 10; 22(8):563-576.  View on PubMed
  14. Othman T, Logan AC, Muffly L, Leonard J, Park J, Shah B, Aldoss I. The Role of CAR T-Cell Therapy in Relapsed/Refractory Adult B-ALL. J Natl Compr Canc Netw. 2024 10; 22(8).  View on PubMed
  15. Peretz CAC, Kennedy VE, Walia A, Delley CL, Koh A, Tran E, Clark IC, Hayford CE, D'Amato C, Xue Y, Fontanez KM, May-Zhang AA, Smithers T, Agam Y, Wang Q, Dai HP, Roy R, Logan AC, Perl AE, Abate A, Olshen A, Smith CC. Multiomic single cell sequencing identifies stemlike nature of mixed phenotype acute leukemia. Nat Commun. 2024 Sep 18; 15(1):8191.  View on PubMed
  16. Gaut D, Oliai C, Boiarsky J, Zhang S, Salhotra A, Azenkot T, Kennedy VE, Khanna V, Olmedo Gutierrez K, Shukla N, Moskoff B, Park G, Afkhami M, Patel A, Jeyakumar D, Mannis G, Logan AC, Jonas BA, Schiller G. Measurable residual disease conversion rate with consolidation chemotherapy in acute myeloid leukemia. Leuk Lymphoma. 2024 Jan; 65(1):69-77.  View on PubMed
  17. Temple WC, Nix MA, Naik A, Izgutdina A, Huang BJ, Wicaksono G, Phojanakong P, Serrano JAC, Young EP, Ramos E, Salangsang F, Steri V, Xirenayi S, Hermiston M, Logan AC, Stieglitz E, Wiita AP. Framework humanization optimizes potency of anti-CD72 nanobody CAR-T cells for B-cell malignancies. J Immunother Cancer. 2023 11 24; 11(11).  View on PubMed
  18. Mandal K, Wicaksono G, Yu C, Adams JJ, Hoopmann MR, Temple WC, Izgutdina A, Escobar BP, Gorelik M, Ihling CH, Nix MA, Naik A, Xie WH, Hübner J, Rollins LA, Reid SM, Ramos E, Kasap C, Steri V, Serrano JAC, Salangsang F, Phojanakong P, McMillan M, Gavallos V, Leavitt AD, Logan AC, Rooney CM, Eyquem J, Sinz A, Huang BJ, Stieglitz E, Smith CC, Moritz RL, Sidhu SS, Huang L, Wiita AP. Structural surfaceomics reveals an AML-specific conformation of integrin β2 as a CAR T cellular therapy target. Nat Cancer. 2023 11; 4(11):1592-1609.  View on PubMed
  19. Logan A. Innovating Simpler and Less Toxic Frontline Management for Adults With ALL. J Clin Oncol. 2024 Jan 20; 42(3):250-252.  View on PubMed
  20. Kantarjian HM, Logan AC, Zaman F, Gökbuget N, Bargou RC, Zeng Y, Zugmaier G, Locatelli F. Survival outcomes in patients with relapsed/refractory or MRD-positive B-cell acute lymphoblastic leukemia treated with blinatumomab. Ther Adv Hematol. 2023; 14:20406207231201454.  View on PubMed

Go to UCSF Profiles, powered by CTSI